New discovery: EGCG in green tea may prevent new coronary pneumonia!

Green tea is popular all over the world, and historically, tea has been used as an herbal medicine to treat various diseases.

On May 25, 2021, Yan Wangjun from Fudan University Cancer Hospital, Yang Zhongshu from the State University of New Jersey, and Zhang Jinsong from Anhui Agricultural University and other teams presented the topic of "Potential protective mechanisms of green tea polyphenol EGCG against COVID-19" in Trends In Food Science & Technology magazine (IF=11.

Green tea contains many kinds of catechins, among which EGCG, which is epigallocatechin gallate, is one of the most abundant catechins.

The researchers in this article mainly reviewed the mechanism of EGCG inhibiting SARS-CoV-2 infection and the different symptoms associated with new coronary pneumonia.

NRF2 activator PB125® down-regulates the mRNA expression of ACE2 and TMPRSS2 in human HepG2 cells.

A large number of studies have shown that EGCG can induce the expression of Nrf2-mediated antioxidant enzymes.

In addition, the author also started from inhibiting SARS-CoV-2 replication-related proteases, preventing oxidative stress and mitochondrial protection, inhibiting endoplasmic reticulum stress, preventing cytokine storms, preventing sepsis, inhibiting thrombosis, inhibiting pulmonary fibrosis, and reducing new coronary pneumonia diabetes The effects of EGCG on new coronary pneumonia have been discussed in many aspects such as the risk of comorbidities, and the author also discussed the safe dose of EGCG in the article.

In conclusion, this article concludes: EGCG inhibits ACE2 (SARS-CoV-2 cell receptor) and TMPRSS2, which mediate virus entry into cells by activating Nrf2.